This study determined the anti-neoplastic activity and nephrotoxicity of
epigenetic inhibitors in vitro. The therapeutic efficacy of
epigenetic inhibitors was determined in human prostate cancer cells (PC-3 and
LNCaP) using the DNA methyltransferase inhibitor 5-azacytidine (5-Aza) and the
histone deacetylase inhibitor trichostatin A (TSA). Cells were also treated with
carbamazepine (CBZ), an anti-convulsant with histone deacetylase inhibitor-like
properties. 5-Aza, TSA or CBZ alone did not decrease MTT staining in PC-3 or
LNCaP cells after 48 hr. In contrast, docetaxel, a frontline chemotherapeutic
induced concentration-dependent decreases in MTT staining. Pretreatment with
5-Aza or TSA increased docetaxel-induced cytotoxicity in LNCaP cells, but not
PC-3 cells. TSA pretreatment also increased cisplatin-induced toxicity in LNCaP
cells. Carfilzomib (CFZ), a protease inhibitor approved for the treatment of
multiple myeloma had minimal effect on LNCaP cell viability, but reduced MTT
staining 50% in PC-3 cells compared to control, and pretreatment with
5-Aza further enhanced toxicity. Treatment of normal rat kidney (NRK) and human
embryonic kidney 293 (HEK293) cells with the same concentrations of epigenetic
inhibitors used in prostate cancer cells significantly decreased MTT staining in
all cell lines after 48 hr. Interestingly, we found that the toxicity of
epigenetic inhibitors to kidney cells was dependent on both the compound and the
stage of cell growth. The effect of 5-Aza and TSA on DNA methyltransferase and
histone deacetylase activity, respectively, was confirmed by assessing the
methylation and acetylation of the CDK inhibitor p21.
Collectively, these data show that combinatorial treatment with epigenetic
inhibitors alters the efficacy of chemotherapeutics in cancer cells in a
compound- and cell-specific manner; however, this treatment also has the
potential to induce nephrotoxic cell injury.